Myasthenia gravis

Stream Lead: A/Prof Anneke van der Walt

MGBase and VALUE-MG

Supported and part-funded by Myasthenia Alliance Australia, MGBase is an expansion of an existing multiple sclerosis registry (MSBase).

Data captured by MGBase include common outcome measures to facilitate comparison with other neuroimmunology diseases, as well as MG-specific outcomes and treatments, including Ig therapy.

Using MGBase data, we will develop new models of clinical demand for Ig in MG. We will also analyse Ig-related adverse events.

The VALUE-MG Study aims to determine the best times to use intravenous immunoglobulin (IVlg) to improve functionality in individuals with MG compared to other treatments.

To express interest in participating at either Alfred Health, Eastern Health or Royal Melbourne Hospital, please contact: value.mg@monash.edu
To express interest in participating at Brain & Mind Centre please contact: value.mg@sydney.edu.au

What is Myasthenia gravis?

Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder that causes muscle weakness. In severe cases, weakness of muscles can lead to respiratory failure necessitating mechanical ventilation, and other serious consequences, such as inability to swallow.

Further research is needed to understand how IVIg is used for MG in Australia, including other therapies (including plasma exchange), clinical benefits to patients, adverse effects, and costs.